Prevalence of complementary and alternative medicine use in cancer patients during treatment.
Jennifer S Yates, Karen M Mustian, Gary R Morrow...
https://pubmed.ncbi.nlm.nih.gov/15711946/Actively Recruiting
Led by LifeBiotic Medical Research Ltd. · Updated on 2026-07-29
60
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of the LCS103 oral herbal formula for preventing recurrence of non-muscle invasive bladder cancer NMIBC. This phase IIA, randomized, controlled, open-label trial will enroll 60 participants to compare the herbal formula plus standard care against standard care alone. The study aims to understand if adding LCS103 to regular treatment can help reduce cancer recurrence and improve patient outcomes. Participants in the investigational group will take three oral tablets of LCS103 twice daily for one year alongside standard care tailored to their cancer risk level. Standard care involves cystoscopic follow-ups and intravesical BCG treatments according to low, intermediate, or high-risk categories. The control group will receive only the recommended standard care for their risk group. After one year, the herbal treatment will stop, and all participants will continue with standard care and monitoring. During the study, participants will be monitored for side effects and adherence to the herbal tablets through pill counts. Researchers will assess bladder cancer recurrence, disease progression, urinary symptoms, quality of life, erectile function in male participants, and several inflammation and urinary measures over the one-year treatment and follow-up period. The total study duration is expected to be two years, including enrollment and final visits.
CONDITIONS
LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Y
Yair Maimon, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
LifeBiotic Medical Research Ltd.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 year
Participants in the investigational arm take LCS103 oral tablets twice daily for one year along with standard care. Participants in the control arm receive standard care only according to their risk group.
Regular cystoscopic follow-ups and BCG treatments as per risk level
Duration - Up to 1 year
After one year, the herbal treatment stops and all participants continue standard care and surveillance to monitor cancer recurrence and health status.
Ongoing cystoscopy and urine cytology follow-ups depending on risk group
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jennifer S Yates, Karen M Mustian, Gary R Morrow...
https://pubmed.ncbi.nlm.nih.gov/15711946/Yair Maimon, Noah Samuels, Zoya Cohen...
https://pubmed.ncbi.nlm.nih.gov/30303021/Sebastien Antoni, Jacques Ferlay, Isabelle Soerjomataram...
https://pubmed.ncbi.nlm.nih.gov/27370177/Yair Maimon, Gilad Amiel, Zoya Cohen...
https://pubmed.ncbi.nlm.nih.gov/38362870/Rebecca L Siegel, Kimberly D Miller, Nikita Sandeep Wagle...
https://pubmed.ncbi.nlm.nih.gov/36633525/Gordon M Cragg, David J Newman
https://pubmed.ncbi.nlm.nih.gov/16009521/Richard S Matulewicz, Gary D Steinberg
https://pubmed.ncbi.nlm.nih.gov/32760227/LifeBiotic Medical Research Ltd.
Lead Sponsor